Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Heron Therapeutics Inc (HRTX) Price & Performance

EPR PropertiesTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Heron Therapeutics Inc — how do they compare? EPR Properties trades at $61.69 (market cap $4.60B), while Heron Therapeutics Inc trades at $0.45 (market cap $84.50M). The key difference: EPR Properties is far larger — about 54.4× Heron Therapeutics Inc's market cap, and EPR Properties pays a 6.19% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

EPRHRTX
Market Cap
$4.60B$84.50M
Sector
Real EstateHealth
52-Week High
$60.81$2.02
52-Week Low
$48.71$0.39
Enterprise Value
$7.66B$182.40M
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.

Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.

Heron Therapeutics Inc

HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.

The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.

Returns comparison

Trailing returns across standard periods

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX